

Overexpression of VEGF₁₂₁, but not VEGF₁₆₅ or FGF-1, improves oxygenation in MCF-7 breast tumours

BM Fenton^{*1}, SF Paoni¹, W Liu¹, S-Y Cheng², B Hu² and I Ding¹

¹Department of Radiation Oncology, University of Rochester Medical Center, Box 704, Rochester, NY 14642, USA; ²Department of Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA

Vascular endothelial growth factor (VEGF) is an intensively studied molecule that has significant potential, both in stimulating angiogenesis and as a target for antiangiogenic approaches. We utilised MCF-7 breast cancer cells transfected with either of two of the major VEGF isoforms, VEGF₁₂₁ or VEGF₁₆₅, or fibroblast growth factor-1 (FGF-1) to distinguish the effects of these factors on tumour growth, vascular function, and oxygen delivery. While each transfectant demonstrated substantially increased tumorigenicity and growth rate compared to vector controls, only VEGF₁₂₁ produced a combination of significantly reduced total and perfused vessel spacing, as well as a corresponding reduction in overall tumour hypoxia. Such pathophysiological effects are of potential importance, since antiangiogenic agents designed to block VEGF isoforms could in turn result in the development of therapeutically unfavourable environments. If antiangiogenic agents are also combined with conventional therapies such as irradiation or chemotherapy, microregional deficiencies in oxygenation could play a key role in ultimate therapeutic success.

British Journal of Cancer (2004) **90**, 430–435. doi:10.1038/sj.bjc.6601539 www.bjcancer.com

© 2004 Cancer Research UK

Keywords: antiangiogenic; hypoxia; image analysis; perfusion; tumour vasculature

Vascular endothelial growth factor (VEGF), perhaps the most critical regulator of angiogenesis in both tumours and normal tissue, is regulated by numerous factors, most notably tissue oxygen level (Shweiki *et al*, 1992). Vascular endothelial growth factor exists as six alternatively spliced isoforms, predominantly VEGF₁₂₁ and VEGF₁₆₅ (Ferrara, 1999), and a number of previous workers have studied vascular changes in tumour lines transfected to overexpress specific isoforms. An almost universal finding among all of the different isoforms has been that overexpression enhances tumorigenesis and tumour progression (Bicknell, 1997). In MCF-7 human breast carcinomas specifically, which normally produce low levels of VEGF, VEGF₁₂₁ transfectants formed faster growing, more vascularised tumours in comparison to wild type (Zhang *et al*, 1995). *In vitro* and *in vivo*, VEGF₁₂₁-transfected MCF-7 tumour cells were shown to be much more tumorigenic and angiogenic than VEGF₁₆₅, perhaps due to the enhanced ability of the VEGF₁₂₁ isoform to freely diffuse from the cells producing it (Zhang *et al*, 2000). Our previous studies have also shown that overexpression of VEGF₁₂₁ or VEGF₁₆₅ by oestrogen-dependent MCF-7 breast cells stimulates breast tumour formation and neovascularisation in an oestrogen-independent fashion in ovariectomised mice, in the absence of 17 β -estradiol treatment (Guo *et al*, 2003). These findings suggested that upregulation of VEGF in oestrogen-dependent breast cancer contributes to the acquisition of oestrogen-independent cancer growth by stimulating tumour angiogenesis and progression through both autocrine and paracrine mechanisms.

Findings in other tumour cell lines have been somewhat mixed. Using transformed murine fibrosarcoma cells (that initially lack VEGF) to specifically express each of the isoforms, it was found that only VEGF₁₆₄ (the murine version of VEGF₁₆₅) could fully rescue tumour growth (Grunstein *et al*, 2000). In this study, vascular densities were unchanged in either the VEGF₁₂₀ or VEGF₁₆₅ transfectants compared to vector controls. In the WM1341B melanoma cell line, however, VEGF₁₆₅ produced much more richly vascularised tumours in transfectants, despite the fact that VEGF₁₂₁ was the predominant isoform in parental cell lines (Yu *et al*, 2002). In gliomas, different VEGF isoforms demonstrated different biological activities than each other at the same site, as well as different activities for the same isoform when implanted at different sites (Guo *et al*, 2001).

Although the effects of VEGF₁₂₁ and VEGF₁₆₅ have been studied in a range of tumour models, techniques have not been available for quantifying the corresponding alterations in tumour blood flow and oxygenation until fairly recently. Since several promising antiangiogenic strategies rely on blocking either VEGF or its receptors (Gerber *et al*, 2000; Bruns *et al*, 2002), such accompanying pathophysiological changes are clearly of interest. Reductions or enhancements in tumour oxygenation could be especially important when combining antiangiogenic agents with conventional therapies, such as radiotherapy and chemotherapy, each of which directly depends on microregional tumour blood flow and oxygenation. The current work utilised MCF-7 breast cancer cells transfected with either VEGF₁₂₁ or VEGF₁₆₅. In addition, since FGF-1 has been similarly associated with highly vascularised tumours (Zhang *et al*, 1997), FGF-1-overexpressing transfectants were included for comparison. Using a combination of immunohistochemistry and image analysis techniques, four pathophysiological indices were determined: (1) total vessel spacing, (2) perfused vessel spacing, (3) % vascular

*Correspondence: Dr BM Fenton; E-mail: bruce.fenton@rochester.edu
Received 4 June 2003; revised 22 October 2003; accepted 5 November 2003

area, and (4) overall tumour hypoxia. Results demonstrate that among these angiogenic growth factors, only VEGF₁₂₁ overexpression produced significant alterations in overall tumour oxygenation.

MATERIALS AND METHODS

Cell lines and reagents

MCF-7 cells were obtained from American Tissue Culture Collection (ATCC, Rockville, MD, USA), and MCF-7 cells that stably express VEGF or FGF-1 were generated by transfecting MCF-7 cells with VEGF₁₂₁, VEGF₁₆₅, or FGF-1 cDNA. The clones that highly expressed exogenous VEGF₁₂₁, VEGF₁₆₅, or FGF-1 were expanded and characterised by methods described previously (Zhang *et al*, 1997; Guo *et al*, 2001; Guo *et al*, 2003). We detected similar levels of VEGF protein in the total cell lysates of both VEGF₁₂₁- and VEGF₁₆₅-expressing cells by Western blotting using an anti-VEGF antibody. In a 48 h cell culture, VEGF₁₂₁-expressing cells secreted 296.6 ng VEGF ml⁻¹ 10⁶ cells⁻¹ and VEGF₁₆₅-expressing cells produced 382.3 ng VEGF ml⁻¹ 10⁶ cells⁻¹ into the conditioned media, as determined by VEGF ELISA assays. We also obtained three additional VEGF-expressing cell clones in each class that express VEGF at similar levels (Guo *et al*, 2003). Human MCF-7 breast tumours were grown in the mammary fat pads of ovariectomised female nude mice as described previously (Guo *et al*, 2001). Briefly, 1 × 10⁷ cells were inoculated into the mammary fat pads of 7–8-week old, ovariectomised female nude mice that were implanted with 17-β estradiol 60-day slow release pellets (Innovative Research of America, Sarasota, FL, USA). The volumes of the tumours were measured using calipers and the formula $\frac{1}{2}ab^2$ (where *a* and *b* are the major and minor tumour dimensions).

DiOC₇ perfusion marker and EF5 hypoxic marker

To visualise blood vessels open to flow, an intravascular stain, DiOC₇, was injected 1 min prior to freezing to preferentially stain cells adjacent to the vessels (Fenton *et al*, 1999). Localised areas of tumour hypoxia were assessed in frozen tissue sections by immunohistochemical identification of sites of 2-nitroimidazole metabolism (EF5 binding) (Fenton *et al*, 1999). EF5 (from NCI) was injected i.v. 1 h before tumour freezing, at which time the EF5 is well distributed throughout even poorly perfused regions of the tumour (Fenton *et al*, 2001). Regions of high EF5 metabolism were visualised immunohistochemically using a Cy3 fluorochrome conjugated to the ELK3-51 antibody, which is extremely specific for the EF5 drug adducts that form when the drug is incorporated by hypoxic cells (Lord *et al*, 1993).

Immunohistochemistry and image analysis

Tumour sections were imaged using a × 20 objective, digitised (Sony DXC9000 3CCD camera), background-corrected, and image-analysed using Image-Pro software (Media Cybernetics, Silver Spring, MD, USA) (Fenton *et al*, 1999). Colour image montages from 16 adjacent microscope fields in each of four tumour regions (encompassing roughly 15 mm²) were automatically acquired and digitally combined under three different staining conditions. First, images of the DiOC₇ were obtained immediately after the frozen sections were sliced on the cryostat. Following staining, the section was returned to the same stage coordinates, and imaged for both hypoxia (EF5) and total vasculature (antipanel endothelial cell antigen, Pharmingen, San Diego, CA, USA). The total vasculature and perfused vasculature images were enhanced using colour segmentation to identify appropriate blood vessels (Fenton *et al*, 1999). Using 'distance map' filtering of the segmented images, individual pixel intensities were converted to levels directly

proportional to the distances between tumour cells and the nearest blood vessel (Fenton *et al*, 2002). Percentage vascular area (defined as total or perfused vessel area/total tissue area) was also determined using Image Pro software. Finally, fluorescent image montages of the EF5/Cy3 staining were quantified by determining the mean pixel intensity of each image (range: 0–255). CCD camera settings were set to a constant shutter speed of 1/60, with constant gain, contrast, and brightness settings.

Statistical analysis

Tumour means were compared using the Student's *t*-test and differences were considered significant for *P* < 0.05.

RESULTS

Overexpression of VEGF₁₂₁, VEGF₁₆₅, or FGF-1 by MCF-7 cells enhanced oestrogen-dependent tumour growth

To determine whether expression of VEGF₁₂₁, VEGF₁₆₅, or FGF-1 by MCF-7 cells enhances MCF-7 breast tumour growth *in vivo*, MCF-7 vector controls, VEGF₁₂₁, VEGF₁₆₅, or FGF-1 cells were implanted orthotopically. At 45 days postimplantation, 40% of mice that received MCF-7/vector cells developed tumours, and volumes averaged 242 ± 50.6 mm³. In contrast, expression of VEGF₁₂₁, VEGF₁₆₅, or FGF-1 not only increased the frequency of MCF-7 tumour formation but also dramatically enhanced tumour growth. As summarised in Table 1, tumour volumes were significantly increased for each of the three transfectants in relation to vector controls (*P* < 0.001).

VEGF₁₂₁, VEGF₁₆₅, and FGF-1 have varying effects on tumour vascularity and perfusion

Since tumour vascularity and hypoxia have been shown to vary with tumour volume (Fenton *et al*, 1988), a separate set of volume-matched tumours was used for the pathophysiological measurements. The mean volumes ± s.e. were as follows: vectors (410 ± 90 mm³), VEGF₁₂₁ (440 ± 30), VEGF₁₆₅ (570 ± 80), and FGF-1 (440 ± 90). Compared to vector controls, total vessel spacing was significantly decreased in both the VEGF₁₂₁ (*P* < 0.001) and VEGF₁₆₅ (*P* = 0.001) tumours, but unchanged in the FGF-1 tumours (see Figures 1A–D and 2A). Note that this decrease in vascular spacing corresponds to the increased vascularity shown in Figure 1. Perfused vessel spacing (Figure 2B), on the other hand, was significantly decreased for both the VEGF₁₂₁ (*P* < 0.001) and FGF-1 (*P* < 0.013) tumours, but not for the VEGF₁₆₅ (*P* = 0.15) (see Figures 1E–H for representative images of the green perfusion stain superimposed on the orange hypoxia stain). To determine whether vascularity or perfusion varied with depth into the tumour, additional low-power image montages (× 10 objective) were also acquired to contrast vascular spacing in the centre (defined by a circular region of diameter 3000 μm) vs the periphery of the tumour cross-section. On average, neither total nor perfused vessel spacing varied significantly with depth into the

Table 1 Tumour formation percentage and tumour volume at 45 days postimplantation

Frequency (%)	Tumour formation	Tumour volume (mm ³)
		Mean ± s.e.
Vector	40	240 ± 50
VEGF ₁₂₁	90	1260 ± 210
VEGF ₁₆₅	86	1640 ± 190
FGF-1	74	760 ± 120




Figure 1 Representative immunohistochemical staining of antipanendothelial cell antigen in panels (A–D), with corresponding images of the DiOC₇ perfusion marker (green) superimposed over the EF5 hypoxia marker (orange), in panels (E–J). Intensely stained orange regions of (E–J) correspond to increased tumour hypoxia. MCF-7 vector is shown in (A) and (E), VEGF₁₂₁ in (B) and (F), VEGF₁₆₅ in (C) and (G), and FGF-1 in (D) and (H). Each of panels (A–H) are portions of the original 4 × 4 composite images taken with a × 20 objective, and the bar in panel (E) equals 100 μm. Panels (I) and (J) are entire 4 × 4 composites taken with a × 10 objective (bar in panel (I) equals 500 μm), illustrating the two general patterns of vascular configuration and hypoxia observed in VEGF₁₆₅ tumours. Peripheral vasculature with centralised hypoxia is shown in panel (I), and a more randomly distributed pattern of vasculature and hypoxia is shown in panel (J).

tumour for any of the four tumour models (data not shown). However, two distinctly different vascular patterns were observed among VEGF₁₆₅ tumours. In roughly half of these tumours, a central region of hypoxia developed that was surrounded by a densely vascularised peripheral rim of vessels (Figure 1I), but in the others, vessels were fairly evenly distributed (Figure 1J).

Vessel diameters and interconnectivity (× 20 objective) were also markedly different among the transfectants, as shown in Figures 1A–D. In comparison to vector controls, percentage areas of both total (open bars in Figure 2C) and perfused (filled bars in Figure 2C) vessels were significantly increased for each of the three transfectants, again most strikingly for the VEGF₁₂₁ tumours.

VEGF₁₂₁ overexpression reduces overall tumour hypoxia

Overall tumour hypoxia was characterised by measuring the mean intensity of the Cy3 conjugated antibody to the EF5 hypoxia marker. As summarised in Figure 2D (and shown by the orange staining in Figures 1E–H), overall tumour hypoxia was unchanged in the VEGF₁₆₅ and FGF-1 tumours, but significantly reduced in the VEGF₁₂₁ tumours ($P = 0.026$) compared to vector controls. This decrease in hypoxia for the VEGF₁₂₁ tumours is in agreement with the striking decrease in perfused vessel spacing observed for these tumours (Figure 2B), which corresponds to a decrease in the distance oxygen must diffuse to reach the tumour cells most distant from the vessels. In the case of the FGF-1 tumours, however, overall tumour hypoxia was unchanged despite a




Figure 2 Effects of VEGF isoforms and FGF-1 on vascular spacing, % vascular area, and overall hypoxia. Data are presented as median distances (mean \pm s.e.) to the nearest total (A) or perfused (B) blood vessel, and increased median distances correspond to decreased vascular densities. An increased disparity between the total and perfused bars for a given tumour type indicates an increased proportion of nonfunctional vessels in that tumour. Data are averaged over four 4×4 image montages (64 fields) from each of 10 MCF-7 vectors (mean volume \pm s.e.m. = 410 ± 90 mm³), six VEGF₁₂₁ tumours (440 ± 30), five VEGF₁₆₅ tumours (570 ± 80), and nine FGF-1 tumours (440 ± 90). (C) Percentage vascular area for total (open bars) and perfused (filled bars) vessels. Asterisks denote statistically significant differences from vector controls. (D) Tumour hypoxia, as measured by overall EF5/Cy3 intensity (mean \pm s.e.), again averaged over four 4×4 image montages.

significant (although less pronounced than in the VEGF₁₂₁ tumours) decrease in perfused vessel spacing.

DISCUSSION

While VEGF is well accepted as an important modulator of tumour growth and vascular development, specific pathophysiological alterations associated with the different VEGF isoforms are less well understood. The current work reaffirms the notion that different VEGF isoforms lead to distinct differences in tumour vascular structure when compared at the same implantation site. In addition, we found that such vascular changes are, in some cases, directly associated with alterations in tumour oxygenation.

In previous studies, results have varied widely in terms of both tumour growth rate and vascular density when different tumour models and implantation sites were considered. Guo *et al* (2001) demonstrated that microenvironmental factors may be important, comparing VEGF₁₂₁- and VEGF₁₆₅-transfected glioma cell lines implanted either subcutaneously (s.c.) or intracranially (i.c.). VEGF₁₆₅ transfectants grew much more rapidly than wild type at either location, with a corresponding increase in vascular density at both. Interestingly, VEGF₁₂₁ transfectants exhibited enhanced vessel growth only when implanted orthotopically in the brain.

Using transfected fibrosarcoma cell lines, Grunstein *et al* (2000) proposed a model in which the different VEGF isoforms preferentially recruit blood vessels to either the tumour interior or periphery. It was suggested that these vascular patterns could possibly relate to the diffusibility of the VEGF₁₂₁ vs the VEGF₁₆₅. In this model, VEGF₁₂₀-overexpressing tumours tended to more effectively recruit systemic vessels, but failed to develop adequate internal vascularisation (Grunstein *et al*, 2000), while VEGF₁₆₄ tumours were capable of inducing both external and internal vascular expansion. In human melanoma transfectants, overall growth rate of the tumours correlated only with the amount of secretable VEGF, rather than on which specific VEGF isoform was overexpressed (Yu *et al*, 2002). Although VEGF₁₂₁ tumours were more densely vascularised at the tumour periphery (with more central necrosis), VEGF₁₆₅ tumours produced a much more densely vascularised plexus of blood vessels overall.

In the current study, human MCF-7 cells were implanted orthotopically in the mammary fat pad. Growth rates of VEGF₁₂₁ and VEGF₁₆₅ transfectants were significantly higher than vector controls and essentially equal to each other, while FGF-1 tumours grew at a somewhat less rapid rate. Both VEGF₁₂₁ and VEGF₁₆₅ produced densely arcading networks of blood vessels of increased vascular diameter. In contrast to both the fibrosarcomas and melanomas, however, spatial heterogeneities in vascular spacing were generally not observed. On average, neither total nor perfused vascular spacing varied as a function of distance from the tumour

surface for any of the MCF-7 transfectants, although roughly half of the VEGF₁₆₅ tumours demonstrated a reduction in vasculature in the tumour centre compared to periphery. Also, in contrast to previous reports in other models, MCF-7 VEGF₁₂₁ transfectants were much more evenly vascularised than the VEGF₁₆₅, as measured by the reduction in vascular spacing. Although the reasons for these disparate findings are unclear, spatially dependent vascular heterogeneities could possibly be related to either specific implantation site or differences in tumour volume.

A key advantage in our method of measuring vascular spacing, rather than the more commonly reported 'vessels field⁻¹' or 'positive pixels mm⁻²', is that vascular spacing is more closely related to the ability of the blood vessels to uniformly supply the tumour with oxygen and nutrients. Especially in tumours containing an uneven distribution of vessels, determinations of mean vascular density can be highly misleading in terms of tumour oxygen delivery. For example, a tumour with a highly localised cluster of dense vascularisation could have an overall vascular density equal to that of a tumour having a reduced but homogeneous distribution of vessels. Clearly, microregional efficiencies in the delivery of either oxygen or chemotherapeutic agents would be quite different between the two. Such differences are apparent when using our 'distance map' measurements of vascular spacing, which depend on vessel number, size, and spatial distribution. Although neither perfused vessel spacing nor tumour hypoxia was significantly altered in the VEGF₁₆₅ tumours, VEGF₁₂₁ tumours demonstrated significant changes in both. This decrease in perfused vessel spacing suggests that these vessels are more efficiently distributed in the VEGF₁₂₁ tumours, which is supported by the significant decrease in overall tumour hypoxia observed in these tumours.

Finally, FGF-1 transfectants have also been reported to form large, vascularised tumours and to confer a more malignant phenotype upon MCF-7 cells, without oestrogen supplementation (Zhang *et al*, 1997). In the current studies, FGF-1 overexpression led to a substantial increase in tumour growth rate, with a significant decrease in the perfused vessel spacing. Conceivably, this increase in perfused vasculature could translate to an increased opportunity for these tumour cells to invade into the circulation and metastasise (Zhang *et al*, 1997).

A major unanswered question raised by this and previous studies is why VEGF₁₂₁ and VEGF₁₆₅ isoforms have such disparate

effects on vascular structure and function among different tumour models. Although tumorigenicity and vascular growth were increased by both in all of the previously cited tumour models, specific alterations in vascular morphology were distinctly different. Interestingly, it has been reported that while VEGF₁₂₁ is the predominant form expressed in human breast carcinomas (Relf *et al*, 1997) and melanomas (Yu *et al*, 2002), the VEGF₁₆₅ variant is predominant in glioblastomas (Berkman *et al*, 1993). This is intriguing in view of the fact that the vascular modification associated with VEGF₁₂₁ or VEGF₁₆₅ transfectants of the three tumour types do not necessarily follow this same pattern. In breast tumours, the predominant variant, VEGF₁₂₁, was also the more effective in inducing extensive tumour vascularisation when overexpressed in that model. In melanomas and gliomas, however, an entirely different relationship holds true, and in each case, the predominant isoform is the less important in terms of promoting vascular development (Guo *et al*, 2001; Yu *et al*, 2002).

Previous studies have speculated that differences in vascular configuration between VEGF₁₂₁ and VEGF₁₆₅ may be related to variations in heparin binding, isoform size, or diffusivity (Guo *et al*, 2001; Yu *et al*, 2002). It has also been hypothesised that variations in isoform expression may confer differential advantages on tumours as they expand in the different sites, each of which may possess different requirements for neovascularisation (Grunstein *et al*, 2000). Further detailed studies are needed to determine whether vascular response is primarily dictated by the immediate microenvironment of the tumour, including proximity to nearby pre-existing host vessels, or instead related to local balances among additional angiogenic growth factors and inhibitors.

ACKNOWLEDGEMENTS

We thank Dr Lurong Zhang of the Lombardi Cancer Center, Georgetown University Medical Center, for providing the FGF-1-transfected MCF-7 tumour cell line. This study was supported by NIH Grant CA52586 (BMF), grants from the Department of Defense: DAMD17-00-1-0420 (BMF), DAMD17-01-1-0375(SYC), and DAMD-17-02-1-0584 (SYC), and the University of Pittsburgh Cancer Institute (SYC).

REFERENCES

- Berkman RA, Merrill MJ, Reinhold WC (1993) Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. *J Clin Invest* **91**: 153–159
- Bicknell R (1997) Mechanistic insights into tumour angiogenesis. In *Tumour Angiogenesis*, Bicknell R, Lewis CE, Ferrara N (eds) pp 19–28. Oxford: Oxford University Press
- Bruns CJ, Shrader M, Harbison MT, Portera C, Solorzano CC, Jauch KW, Hicklin DJ, Radinsky R, Ellis LM (2002) Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. *Int J Cancer* **102**: 101–108
- Fenton BM, Lord EM, Paoni SF (2001) Effects of radiation on tumor intravascular oxygenation, vascular configuration, hypoxic development, and survival. *Radiat Res* **155**: 360–368
- Fenton BM, Paoni SF, Beauchamp BK, Ding I (2002) Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis. *Br J Cancer* **86**: 1831–1836
- Fenton BM, Paoni SF, Lee J, Koch CJ, Lord EM (1999) Quantification of tumor vascular development and hypoxia by immunohistochemical staining and HbO₂ saturation measurements. *Br J Cancer* **79**: 464–471
- Fenton BM, Rofstad EK, Degner FL, Sutherland RM (1988) Cryospectrophotometric determination of tumor intravascular oxyhemoglobin saturations: dependence on vascular geometry and tumor growth. *J Natl Cancer Inst* **80**: 1612–1619
- Ferrara N (1999) Vascular endothelial growth factor: molecular and biological aspects. *Curr Top Microbiol Immunol* **237**: 1–30
- Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N (2000) Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. *Cancer Res* **60**: 6253–6258
- Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS (2000) Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. *Mol Cell Biol* **20**: 7282–7291
- Guo P, Fang Q, Tao HQ, Schafer CA, Fenton BM, Ding I, Hu B, Cheng SY (2003) Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth *in vivo*. *Cancer Res* **63**: 4684–4691
- Guo P, Xu L, Pan S, Brekken RA, Yang ST, Whitaker GB, Nagane M, Thorpe PE, Rosenbaum JS, Su HH, Cavenee WK, Cheng SY (2001) Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. *Cancer Res* **61**: 8569–8577
- Lord EM, Harwell L, Koch CJ (1993) Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. *Cancer Res* **53**: 5721–5726

- Relf M, Lejeune S, Scott PE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. *Cancer Res* **57**: 963–969
- Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature* **359**: 843–845
- Yu JL, Rak JW, Klement G, Kerbel RS (2002) Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. *Cancer Res* **62**: 1838–1846
- Zhang HT, Craft P, Scott PAE, Ziche M, Weich HA, Harris AL, Bicknell R (1995) Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. *J Natl Cancer Inst* **87**: 213–219
- Zhang H-T, Scott PAE, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, Bicknell R (2000) The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants *in vivo*. *Br J Cancer* **83**: 63–68
- Zhang L, Kharbanda S, Chen D, Bullocks J, Miller DL, Ding IYF, Hanfelt J, McLeskey SW, Kern FG (1997) MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. *Oncogene* **15**: 2093–2108